NO20020801L - Farmasoytisk materiale av etinylestradiol og drospirenon for anvendelse som antikonsepsjonsmiddel - Google Patents

Farmasoytisk materiale av etinylestradiol og drospirenon for anvendelse som antikonsepsjonsmiddel

Info

Publication number
NO20020801L
NO20020801L NO20020801A NO20020801A NO20020801L NO 20020801 L NO20020801 L NO 20020801L NO 20020801 A NO20020801 A NO 20020801A NO 20020801 A NO20020801 A NO 20020801A NO 20020801 L NO20020801 L NO 20020801L
Authority
NO
Norway
Prior art keywords
daily dosage
drospirenone
approx
ethinyl estradiol
dosage units
Prior art date
Application number
NO20020801A
Other languages
English (en)
Other versions
NO326860B1 (no
NO20020801D0 (no
Inventor
Wolfgang Heil
Juergen Hilmann
Ralph Lipp
Renate Heithecker
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20020801(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20020801D0 publication Critical patent/NO20020801D0/no
Publication of NO20020801L publication Critical patent/NO20020801L/no
Publication of NO326860B1 publication Critical patent/NO326860B1/no
Priority to NO20091809A priority Critical patent/NO20091809L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

j Det beskrives farmasøytiske materialer som omfatter som et første aktive 6P,7p,15P,16P-dimetylen-3-okso-17a-pregn-4-en-21,17-karbolakton (drospirenon) i en mengde korresponderende til en daglig dosering, ved administrering av materialet, fra ca. 2 mg til ca. 4 mg, og.som et andre aktive middel 17a-etinylestradiol (etinylestradiol) i en mengde korresponderende til daglig dosering av fra ca. 0,01 mg til ca. 0,05 mg, sammen med eller flere farmasøytisk akseptable bærere eller eksipienter.I en spesifikk utførelse omfatter materialet et antall separat pakkede og individuelt fjern-bare daglige doseringsenheter plassert i en pakningsenhet og tiltenkt for oral administrering på minst 21 påfølgende dager, hvorpå nevnte daglige doseringsenheter omfatter kombinasjonen av drospirenon og etinylestrediol. Materialet kan videre omfatte 7 eller mindre daglige doseringsenheter som inneholder intet aktivt middel, eller som kun inneholder etinylestradiol.
NO20020801A 1999-08-31 2002-02-19 Farmasoytisk sammensetning av etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel NO326860B1 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20091809A NO20091809L (no) 1999-08-31 2009-05-07 Farmasoytisk materiale av entinylestradiol og drospirenon for anvendelse som antikonsepsjonsmiddel

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38627499A 1999-08-31 1999-08-31
EP99202826 1999-08-31
PCT/IB2000/001213 WO2001015701A1 (en) 1999-08-31 2000-08-31 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Publications (3)

Publication Number Publication Date
NO20020801D0 NO20020801D0 (no) 2002-02-19
NO20020801L true NO20020801L (no) 2002-04-26
NO326860B1 NO326860B1 (no) 2009-03-02

Family

ID=26153359

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020801A NO326860B1 (no) 1999-08-31 2002-02-19 Farmasoytisk sammensetning av etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel

Country Status (26)

Country Link
EP (4) EP1598069B1 (no)
JP (2) JP4354667B2 (no)
KR (2) KR101019361B1 (no)
AT (3) ATE429231T1 (no)
AU (4) AU780330B2 (no)
BG (1) BG66114B1 (no)
BR (1) BR0014159A (no)
CY (3) CY1108990T1 (no)
CZ (1) CZ300514B6 (no)
DE (5) DE60006692T2 (no)
DK (3) DK1214076T3 (no)
EE (1) EE05128B1 (no)
ES (3) ES2325589T3 (no)
HK (1) HK1047247B (no)
HR (1) HRP20070188B1 (no)
HU (1) HU227207B1 (no)
IL (1) IL148339A0 (no)
ME (2) MEP36008A (no)
NO (1) NO326860B1 (no)
NZ (1) NZ517845A (no)
PL (1) PL199028B1 (no)
PT (3) PT1380301E (no)
RS (3) RS50262B (no)
SI (3) SI1380301T1 (no)
TW (1) TWI276436B (no)
WO (1) WO2001015701A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1598069B1 (en) * 1999-08-31 2009-04-22 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
IL150775A0 (en) * 2000-01-18 2003-02-12 Schering Ag Drospirenone for hormone replacement therapy
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
JP5350572B2 (ja) * 2000-12-20 2013-11-27 バイエル ファーマ アクチエンゲゼルシャフト シクロデキストリン−ドロスピレノン封入複合体
CA2483554A1 (en) * 2002-04-26 2003-11-06 Schering Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
CA2558393A1 (en) * 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
WO2006102750A1 (en) * 2005-03-30 2006-10-05 Genpharm Inc. Combined-step process for pharmaceutical compositions
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1900359A1 (en) * 2006-09-16 2008-03-19 KAIROSmed GmbH Oral modified release formulations containing drospirenon and 8-prenylnaringenin for use in female contraception
JP2010503632A (ja) * 2006-09-16 2010-02-04 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 経口改良放出製剤
BRPI0810049A2 (pt) * 2007-04-05 2015-05-05 Bayer Schering Pharma Ag Regime de drospirenona/17beta-estradiol, produto de combinação farmacêutica e kit para realizar esse regime
HUP0700826A3 (en) * 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
TW200946542A (en) * 2008-03-10 2009-11-16 Vladimir Hanes New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009112231A2 (en) * 2008-03-10 2009-09-17 Schuermann Rolf New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
MX356702B (es) * 2010-04-15 2018-06-11 Bayer Ip Gmbh Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) * 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
IT202100008834A1 (it) 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
AR128632A1 (es) * 2022-03-01 2024-05-29 Chemo Res S L Anticonceptivo oral masticable de drospirenona

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3051167C3 (de) * 1979-01-24 1994-11-24 Minnesota Mining & Mfg Fluorierte Alkohole
DE3051166C2 (en) 1980-06-11 1990-10-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Compsns. for contraception or treatment of gynaecological disorders
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE3682130D1 (de) * 1985-07-15 1991-11-28 Japan Res Dev Corp Verfahren zur herstellung von ultrafeinen organischen verbindungen.
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
ZA939566B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for dry blend compression od medicaments.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
DK0782449T3 (da) * 1994-09-22 2003-08-04 Akzo Nobel Nv Fremgangsmåde til fremstilling af doseringsenheder ved vådgranulering
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
ES2229378T3 (es) * 1996-07-26 2005-04-16 Wyeth Anticonceptivo oral.
WO1998004269A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
EP1598069B1 (en) * 1999-08-31 2009-04-22 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
IL150775A0 (en) * 2000-01-18 2003-02-12 Schering Ag Drospirenone for hormone replacement therapy

Also Published As

Publication number Publication date
AU2009200247B2 (en) 2010-07-01
SI1214076T1 (en) 2004-06-30
JP4354667B2 (ja) 2009-10-28
DE60006692D1 (de) 2003-12-24
CY1109252T1 (el) 2014-07-02
WO2001015701A1 (en) 2001-03-08
RS20090134A (sr) 2009-11-10
BG66114B1 (bg) 2011-05-31
AU2009200247A1 (en) 2009-02-19
ATE420648T1 (de) 2009-01-15
DE122009000006I2 (de) 2012-03-22
KR20020040798A (ko) 2002-05-30
PL354406A1 (pl) 2004-01-12
AU2010226924A1 (en) 2010-10-28
PT1214076E (pt) 2004-04-30
IL148339A0 (en) 2002-09-12
HUP0202500A3 (en) 2004-04-28
KR100857344B1 (ko) 2008-09-05
HK1047247A1 (en) 2003-02-14
DE122009000006I1 (de) 2009-05-07
EP1598069B1 (en) 2009-04-22
EP1598069A2 (en) 2005-11-23
JP2003508441A (ja) 2003-03-04
HUP0202500A2 (en) 2002-10-28
JP2009143959A (ja) 2009-07-02
DK1380301T3 (da) 2009-04-20
ATE254464T1 (de) 2003-12-15
ATE429231T1 (de) 2009-05-15
ES2211580T3 (es) 2004-07-16
ES2325589T3 (es) 2009-09-09
HK1082432A1 (en) 2006-06-09
DE60041421D1 (de) 2009-03-05
ES2319750T3 (es) 2009-05-12
EP1380301B1 (en) 2009-01-14
HRP20070188A2 (en) 2007-07-31
EE05128B1 (et) 2009-02-16
YU14502A (sh) 2006-01-16
TWI276436B (en) 2007-03-21
NO326860B1 (no) 2009-03-02
AU2005202046B2 (en) 2008-11-20
KR101019361B1 (ko) 2011-03-07
CY1108990T1 (el) 2014-02-12
BR0014159A (pt) 2002-05-07
DE122009000007I2 (de) 2011-07-21
RS50262B2 (sr) 2018-10-31
EP1380301A1 (en) 2004-01-14
SI1380301T1 (sl) 2009-06-30
KR20070067248A (ko) 2007-06-27
PT1598069E (pt) 2009-07-20
RS50262B (sr) 2009-07-15
NO20020801D0 (no) 2002-02-19
CZ300514B6 (cs) 2009-06-03
DE60042089D1 (de) 2009-06-04
EE200200110A (et) 2003-06-16
AU2005202046B9 (en) 2008-12-11
DK1214076T3 (da) 2004-02-23
CZ2002615A3 (cs) 2002-08-14
HK1047247B (en) 2004-07-23
DK1598069T3 (da) 2009-07-06
HK1061968A1 (en) 2004-10-15
SI1598069T1 (sl) 2009-10-31
EP1214076A1 (en) 2002-06-19
PT1380301E (pt) 2009-03-30
AU780330B2 (en) 2005-03-17
AU6589500A (en) 2001-03-26
ME00329B (me) 2011-05-10
EP1598069A3 (en) 2006-04-05
DE60006692T2 (de) 2004-09-23
DE122009000007I1 (de) 2009-05-07
EP2044941A1 (en) 2009-04-08
HRP20070188B1 (hr) 2015-06-19
NZ517845A (en) 2004-12-24
AU2005202046A1 (en) 2005-06-09
MEP36008A (hr) 2011-02-10
PL199028B1 (pl) 2008-08-29
EP1214076B1 (en) 2003-11-19
HU227207B1 (en) 2010-11-29
CY2009015I1 (el) 2014-02-12
CY2009015I2 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
YU14502A (sh) Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
NO20091809L (no) Farmasoytisk materiale av entinylestradiol og drospirenon for anvendelse som antikonsepsjonsmiddel
BG66095B1 (bg) Хидрофилен състав с контролирано освобождаване съдържащ прежелатинирано нишесте в препарат
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
RU2004113305A (ru) Комбинированный эстрогенный/гестагенный препарат и его применение
AR084229A2 (es) Preparado polifasico para la contracepcion a base de un estrogeno natural
CY1108265T1 (el) Στερεη διαστοματικη φαρμακευτικη μορφη για αντισυλληψη
KR970706004A (ko) 호르몬 약물 및 에스트로겐 결핍을 치유하기 위한 그의 용도(novel hormonal medicaments and use thereof for correcting oestrogen deficiencies)
KR890009407A (ko) 폐경기증세 및 골다공증의 치료를 위한 약학적 투여단위
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
NO20072687L (no) Farmasoytisk prevensjonspreparat
RU2000115313A (ru) Схемы приема гестаген-анти-гестагена
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
JO2213B1 (en) A pharmaceutical composition for use as a contraceptive method
ECSP003721A (es) Una composicion farmaceutica para ser usada como anticonceptivo
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
EP2305267A3 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
HRP20020666B1 (hr) Drospirenon za hormonsku nadomjesnu terapiju
CO5280075A1 (es) Drospirenona para terapia de reemplazo de hormonas

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

REER Request for administrative reevaluation of patent

Opponent name: GEDEON RICHTER PLC, HU

CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

MK1K Patent expired